Acute Exacerbations of COPD (AECOPD) - Management

Definition

Precipitating Causes

• Harrison's 22E, p. 2302

Differential Diagnosis

• Pneumonia
• Pulmonary embolism (incidence is increased in AECOPD)
• Acute decompensated heart failure
• Pneumothorax
• Cardiac ischemia
• Pleural effusion
• Large airway tumor
• Washington Manual of Medical Therapeutics, p. 319

Severity Classification (GOLD / Rome Proposal)

Initial Assessment

History

• Degree and change in dyspnea (activities of daily living)
• Fever, sputum character change, wheezing, GI symptoms
• Frequency and severity of prior exacerbations (prior hospitalization = biggest risk factor for re-hospitalization)
• Comorbidities (heart disease, diabetes)

Physical Examination

• Tachycardia, tachypnea
• Use of accessory muscles, intercostal retractions
• Ability to speak in complete sentences
• Mental status (confusion/somnolence suggests hypercarbia)
• Asymmetric chest findings (pneumothorax), paradoxical abdominal wall movement
• Signs of right or left heart failure

Investigations

• Harrison's 22E, pp. 2302-2303; Rosen's Emergency Medicine, p. 2560

Indications for Hospitalization

• Significant increase in symptom severity
• Severe underlying COPD (e.g., FEV₁ very low at baseline)
• Respiratory acidosis / hypercarbia
• New or worsening hypoxemia
• Significant comorbidities (heart failure, arrhythmia)
• Failure to respond to initial outpatient/ED treatment
• Insufficient home support or inability to manage at home
• Diagnostic uncertainty
• Washington Manual, p. 320; Goldman-Cecil Medicine, p. 3148

Indications for ICU Admission

• Need for invasive mechanical ventilation
• Hemodynamic instability
• Severe dyspnea not responding to therapy
• Altered mental status
• Persistent or worsening hypoxemia, hypercapnia, or respiratory acidosis despite supplemental O₂ and NIV

Pharmacological Management

1. Bronchodilators (First-Line)

• In the emergency setting, nebulizers are preferred over MDIs requiring complex technique
• Use air-driven nebulizers (not oxygen-driven) when possible
• Continuous nebulization is NOT indicated
• Methylxanthines (theophylline) are not recommended due to poor side-effect profile without added benefit
• Washington Manual, p. 320; Rosen's EM, p. 2574; GOLD 2026

2. Systemic Corticosteroids

• Prednisone 40 mg/day orally for 5 days (5-day courses are as effective as longer courses)
• Parenteral route (methylprednisolone) only if patient cannot tolerate oral medication
• Benefits: decreased recovery time, improved oxygenation, improved FEV₁, shorter hospital stay
• Oral and parenteral bioavailability are similar - prefer oral when tolerated
• Rosen's EM, p. 2579; GOLD 2026

3. Antibiotics

• Increased dyspnea + increased sputum volume + increased sputum purulence (all three = strongest indication)
• Patients requiring NIV or mechanical ventilation (clear mortality benefit in these)
• CRP-guided or procalcitonin-guided prescribing can reduce unnecessary antibiotic use in non-critically ill patients

Note: In critically ill patients on ICU, PCT-guided antibiotic therapy was associated with worse 3-month mortality - do NOT withhold antibiotics based on PCT in the ICU.

• Washington Manual, p. 320; Goldman-Cecil, p. 3150; Rosen's EM, p. 2582-2584

Oxygen Therapy

• Target SpO₂: 88-92% (controlled oxygen therapy to avoid hypercapnic drive suppression)
• High-flow nasal therapy (HFNT) is increasingly used for hypoxemic AECOPD
• Avoid high-concentration uncontrolled oxygen

Ventilatory Support

Non-Invasive Ventilation (NIV) - First-Line for Respiratory Failure

• Severe dyspnea with increased work of breathing
• Moderate-to-severe respiratory acidosis (pH <7.35) + hypercapnia (PCO₂ >45 mmHg)
• Persistent hypoxemia despite supplemental oxygen

• Decreased respiratory rate
• Increased tidal volume and minute ventilation
• Reduced need for endotracheal intubation
• Decreased in-hospital mortality
• Shorter ICU and hospital length of stay
• Mechanism: improved alveolar ventilation and respiratory mechanics
• Fishman's Pulmonary Diseases, p. 2630; Roberts and Hedges' Clinical Procedures, p. 231; Murray & Nadel's Respiratory Medicine

Key point: NIV must be initiated early alongside standard medical therapy. Late initiation (after medical treatment failure) eliminates the survival and intubation-reduction benefits.

Contraindications to NIV

• Respiratory or cardiac arrest
• Hemodynamic instability
• Uncooperative or agitated patient
• High aspiration risk
• Inability to protect airway
• Recent upper airway/GI surgery

Invasive Mechanical Ventilation

• Respiratory arrest
• Severe respiratory failure not responding to NIV
• Decreased consciousness / significant agitation
• Hemodynamic instability
• Massive aspiration
• Persistent inability to clear secretions
• Harrison's 22E, p. 2303; Tintinalli's EM, p. 1745

Discharge Criteria and Follow-Up

• Patient on maintenance therapy every 4 hours or less
• Walking stable (patient ambulatory)
• Eating, sleeping not disturbed by dyspnea
• Clinically stable for 12-24 hours
• ABG stable for 12-24 hours
• Patient/family understands medication use

• Initiate/optimize long-acting bronchodilators (LABDs) as soon as possible
• If ≥1 moderate/severe exacerbation and elevated blood eosinophil count: add ICS to dual bronchodilator regimen at discharge
• Full recovery takes 4-6 weeks - some patients never return to pre-exacerbation baseline
• Review COPD management plan and comorbidities
• Implement exacerbation prevention strategies (vaccination, smoking cessation, pulmonary rehabilitation)

Prevention of Future Exacerbations

Summary Algorithm

AECOPD suspected
    ↓
Exclude mimics (PE, pneumonia, CHF, pneumothorax)
    ↓
Assess severity → Mild / Moderate / Severe
    ↓
All patients: SABA ± SAAC bronchodilators
Moderate/Severe: + systemic steroids (prednisone 40mg x 5d)
Purulent sputum/infection signs: + antibiotics x 5d
    ↓
Hypoxemia → controlled O₂ (SpO₂ 88-92%)
    ↓
Respiratory acidosis / increased WOB → NIV (BiPAP)
    ↓
NIV failure / contraindications → invasive MV
    ↓
Discharge with LABD optimization, follow-up in 1-4 weeks

• Top section - Initial workup and exclusion of mimics (PE, pneumonia, CHF, pneumothorax)
• Three color-coded severity lanes:
  • 🟢 Mild - SABA-responsive, SpO₂ ≥92% on room air → direct discharge pathway
  • 🟡 Moderate - needs bronchodilators + steroids + antibiotics (if purulent) → re-assess response before discharge vs. ward admission
  • 🔴 Severe - respiratory acidosis, altered mental status, hemodynamic instability → admit, trial NIV (BiPAP), escalate to invasive MV + ICU if NIV fails or is contraindicated
• Bottom discharge checklist - ensures safe discharge criteria are met before sending a patient home